Anjul Agarwal
anjul_g@rediffmail.com
International Journal of ChemTech Research
IJCTR
0974-4290
2455-9555
10.20902/CT
http://www.sphinxsai.com/chemtech.php
2018
11
11
Synthesis and evaluation of some newerthiazolidinonyl substituted quinazolinones as potent anticonvulsant agents
Archana
1
Sachin
Saini
2
Medicinal Chemistry Laboratory , Department of Chemistry , Meerut College , Meerut
( U. P.) 250001 , India
Department of Chemistry, Mewar University, Rajasthan, India
2018
09
16
111102
10.20902/IJCTR.2018.111102
http://dx.doi.org/10.20902/IJCTR.2018.111102
A new series of 3-(Aminoacetylthiosemicarbazido)-2-methyl mono substituted
quinazolin-4(3H)-ones(3-4),3-(Aminoacetyl thiosemicarbazido substituted arylidene)-2-
methyl monosubstituted-quinazolin-4(3H)-ones (5-14) and 3-[3’-( Amino acetyl
thiosemicardazido)-4’-oxo-2’-(substitutedaryl)-1’-thiazolidinonyl]-2-methyl mono substitute
dquinazolinones (15-24) were synthesised and evaluated for anticonvulsant activity. All these
compounds were screened in vivo, for their anticonvulsant activity and acute toxicity.
Compound 22,3-[3’-(Amino acetyl thiosemicardazido)-4’-oxo-2’-(3-methoxy-4hydroxy
arylidene)-1’-thiazolidinonyl]-2-methyl-6-bromoquinazolinones, was found to be most potent
compound of this series, more potent (exhibiting 90%protection) than standard drug phenytoin
sodium (having 80% protection). The homogeneity of all the compounds have been
established by elemental analysis, IR and 1H-NMR spectroscopy
http://sphinxsai.com/2018/ch_vol11_no11/1/(09-16)V11N11CT.pdf
Thiazolidinones
quinazolinones
anticonvulsant activity
acute toxicity
Eur. J. Med. Pharm.
Loscher W.
342
1
1998
Current Treatment Options in neurology
Leppik I.E.
10
239
2008
Bioorg. Med. Chem.
Chen L., Sun X.Y., Chai K.Y.
15
6775
2007
Brain & Development
Kubota M., Sakakihora Y.
22
230
2000
Epilepsia
French J.A.
40
803
1999
Digest J. Nanomaterials and Biostructures
Patil V.M., Sinha R., Masand N.
4
471
2009
Arch. Int. Pharmacoldyn.
Swift JK, Dickens EA, Beackers BA
128
112
1960
J. Taiban University Med. Sci.
Zayed F
9
104
2014
Med. Chem. Res.
Hasan H, Akhter M, Akhter W, Ali I, Zaheen M, Ahsan I, Mahmood D
20
1357
2011
Eur. J. Med. Chem.
Archana, Srivastava VK, Kumar A
37
873
2002
J. Med. Chem.
Wolfe JF, Rathman TL, sleeve MC, Campbell JA, Grennwood TD
33
161
1990
Saudi J. Med. Pharm. Sci.
Archana
1
42
2015
Bull.Fac. Pharm. Cairo. Univ.
Abbas SE
45
119
2007
Molecules
Georgy H, Gawad NA, Abbas S
13
2557
2008
Int. J.
TechnoChem Res.
Archana
2
1
2016
Bioorg. and Med. Chem.
Archana, Srivastava VK, Kumar A
12
1257
2004
Indian J. Chem.
Manoj K, Srivastava S, Bharati M, Nizamuddin N
40
342
2002
J. Med. Chem.
Ager R, Harrison DR, Kennwell PD, Taylor JB
20
379
1977
ARKIVOC
Kashaw SK, Kashaw V, Mishra P, Jain NK
14
17
2008
Eur. J. Med. Chem.
Giri RS, Thaker HM, Giordano T, Wiiliams J
44
2184
2009
Indian J. Chem.
Bansal E, Ram T, Sharma S, Tyagi M, Archana, Rani P, et. al
40B
307
2001
Indian J. Chem.
Rani P, Archana, Srivastava VK, Kumar A
41B
2642
2002
Indian J. Chem.
Kumar A, Sharma S, Bajaj K, Bansal D, Sharma S, Archana, et. al
42B
1979
2003
ARKIVOC
Mahendra RS, Ghodake M, Kailash GB, Sashikant VB, Ana N, et al
14
58
2007
Sch. Acad. J. Pharm.
Bhaumik A., Chandra Ma, Saha S, Mastanaiah J, Visalakshi T
3
128
2014
Bioorg. Med. Chem.
Jain AK, Vaidya A, Ravichandran V, Kashaw SK
20
3378
2012
Farmaco
Ergenc N, Capan G
49
133
1994
Eur. J. Med. Chem.
Agarwal A, Lata S, Saxena KK, Srivastava VK, Kumar A
41
1223
2006
Int. J. TechnoChem. Res.
Archana
2
121
2016
J. Neurophysiol.
Toman JEP, Swinyard EA. Goodman LS
9
231
1946
Smith QE.:Pharmacological Screening Test Progress in Med. Chem., Vol. 1, Butterworth, London,
1960, 1-33